Precigen (NASDAQ:PGEN) Shares Up 5.1% – What’s Next?

Precigen, Inc. (NASDAQ:PGEN) was up 5.1% during trading on Monday . The stock traded as high as $4.30 and last traded at $4.3710. Approximately 865,979 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 4,301,535 shares. The stock had previously closed at $4.16.

Analysts Set New Price Targets

A number of analysts have recently commented on PGEN shares. HC Wainwright upped their price target on Precigen from $8.50 to $9.00 and gave the company a “buy” rating in a research note on Friday, November 14th. Wall Street Zen cut Precigen from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Precigen Stock Performance

The company has a fifty day moving average price of $3.99 and a two-hundred day moving average price of $3.16. The company has a market capitalization of $1.56 billion, a P/E ratio of -3.17 and a beta of 1.16. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.04 and a quick ratio of 3.95.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $2.92 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a positive return on equity of 1,066.10% and a negative net margin of 3,912.92%. Equities analysts forecast that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jeffrey B. Kindler sold 106,837 shares of the stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $3.38, for a total transaction of $361,109.06. Following the sale, the director owned 346,070 shares of the company’s stock, valued at approximately $1,169,716.60. This represents a 23.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Randal J. Kirk sold 1,900,036 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $4.18, for a total transaction of $7,942,150.48. Following the completion of the transaction, the director directly owned 341,189 shares of the company’s stock, valued at approximately $1,426,170.02. This represents a 84.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,782,833 shares of company stock worth $26,765,972 over the last quarter. 47.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Precigen

A number of large investors have recently bought and sold shares of PGEN. Deutsche Bank AG increased its stake in shares of Precigen by 35.3% during the first quarter. Deutsche Bank AG now owns 91,031 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 23,729 shares during the period. Nuveen LLC bought a new position in Precigen in the 1st quarter worth about $275,000. MetLife Investment Management LLC purchased a new stake in Precigen during the 1st quarter valued at $124,000. Adage Capital Partners GP L.L.C. boosted its position in shares of Precigen by 3.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock valued at $16,801,000 after buying an additional 410,595 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Precigen by 216.9% in the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 43,245 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.